Regeneron Pharmaceuticals (REGN) said Thursday that its supplemental biologics license application for Eylea HD 8 mg injection has been accepted for priority review by the US Food and Drug Administration, with a decision expected by Aug. 19.
The company said it is seeking approval for Eylea, or aflibercept, to treat macular edema following retinal vein occlusion and to expand Eylea HD's dosing schedule to include every 4-week dosing across approved indications.
The submission is backed by data from a phase 3 trial, which showed that patients who received Eylea HD every 8 weeks achieved similar vision outcomes compared with those receiving the drug every 4 weeks, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.